Keywords
How to Cite
Abstract
With aging, androgen levels gradually decline. In adult men, the decline in testosterone levels associated with signs and symptoms is presented as androgen deficiency of male aging (ADEM), some of these signs and symptoms are: decreased libido, depression, erectile dysfunction, anemia, decreased bone density and muscle mass. Testosterone is a hormone belonging to the androgen class. Its function is related to the maintenance of the sexual organs, but it also has an effect on non-reproductive organs such as the liver, inducing the synthesis of hepatic lipases and coagulation factors. Testosterone is also associated with increased activity of the fibrinolytic system and antithrombin III, constituents of the physiological hemostatic mechanism against blood loss and fluidity. Given the importance of testosterone, its replacement has been widely prescribed for men without a diagnosis of hypogonadism, given that adults after the age of 60 have testosterone levels below the lower limits for adults. In view of the above, the aim of this study is to carry out a literature review on the benefits of testosterone replacement treatment on hemostasis in men with androgen deficiency in male aging. This is a descriptive literature review with a qualitative approach. The study population will consist of articles in Portuguese, English and Spanish, obtained from the Scielo, Google Scholar and PubMed databases. A total of 53 articles were selected for sampling, 33 of which met the inclusion criteria. In this context, testosterone replacement therapy has a protective endothelial action, increasing the activity of the fibrinolytic system and antithrombin activity, which are responsible for dissolving and neutralizing clots.
References
BAILLARGEON, Jacques et al. Risk of venous thromboembolism in men receiving testosterone therapy. In: Mayo Clinic Proceedings. Elsevier, 2015.
BECHER, E, Torres LO, Glina S. Contraindicações para a reposição de testosterone na Deficiência Androgênica do Envelhecimento Masculino. Consenso Latino-Americano sobre DAEM. Sociedad Latinoamericana de Medicina Sexual. Sao Paulo: Planmark, 2013
BERGER, Markus et al. Hemostasia: uma breve revisão. Revista Caderno Pedagógico, v. 11, n. 1, 2014.
BRODIN, Ellen et al. Testosterone, hemostasis, and cardiovascular diseases in men. In: Seminars in thrombosis and hemostasis. Thieme Medical Publishers, 2011.
FONSECA, Guilherme Wesley Peixoto da et al. Testosterona e doença cardiovascular: do tratamento ao uso abusivo. Rev. Soc. Cardiol. Estado de Säo Paulo, p. 393-399, 2019.
GANTI, Apar Kishor; POTTI, Anil; YEGNANARAYAN, Radha. Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 levels in acute myocardial infarction. Pathophysiology of haemostasis and thrombosis, v. 32, n. 2, p. 80-84, 2002.
GEBARA, Otavio CE et al. Efeitos cardiovasculares da testosterona. Arquivos brasileiros de cardiologia, v. 79, n. 6, p. 644-649, 2002.
GUYTON, Arthur C.; HALL, Jhon E. Guyton e Hall fundamentos da fisiologia. 13. ed. Rio de Janeiro: Elsevier, 2017.
HAK, AE, Witteman, JC, de Jong, FH, Geerlings, MI, Hofman, A., e Pols, HA . Baixos níveis de andrógenos endógenos aumentam o risco de aterosclerose em homens idosos: The Rotterdam Study. J. Clin. Endocrinol. 2002.
HAYWARD, Christopher S.; KELLY, Raymond P.; COLLINS, Peter. The roles of gender, the menopause and hormone replacement on cardiovascular function. Cardiovascular research, v. 46, n. 1, p. 28-49, 2000.
JIN, Hong et al. Physiological testosterone stimulates tissue plasminogen activator and tissue factor pathway inhibitor and inhibits plasminogen activator inhibitor type 1 release in endothelial cells. Biochemistry and cell biology, v. 85, n. 2, p. 246-251, 2007.
LORENZI, Therezinha Ferreira. Atlas de Hematologia: clínica hematológica ilustrada. São Paulo: Guanabara Koogan, p.684, 2005.
MALKIN, C. J. et al. Testosterone as a protective factor against atherosclerosis--immunomodulation and influence upon plaque development and stability. The Journal of endocrinology, v. 178, n. 3, p. 373-380, 2003.
PUGH, Peter J. et al. Os níveis de testosterona biodisponível caem agudamente após infarto do miocárdio em homens: associação com fatores fibrinolíticos. Pesquisa endócrina, v. 28, n. 3, pág. 161-173, 2002.
REIS, Christiane Vieira et al. Avaliação de coagulação, fibrinólise e proteína C em pacientes de risco e com doenças coronarianas. Jornal Brasileiro de Patologia e Medicina Laboratorial, v. 39, n. 1, p. 07-13, 2003.
SHORES, Molly M. et al. Testosterone treatment and mortality in men with low testosterone levels. The Journal of Clinical Endocrinology & Metabolism, v. 97, n. 6, p. 2050-2058, 2012.
SILVA, Kassio Rios; LINARTEVICHI, Vagner Fagnani. DEFICIÊNCIA ANDROGÊNICA DO ENVELHECIMENTO MASCULINO E A REPOSIÇÃO DE TESTOSTERONA. Fag Journal Of Health (Fjh), Cascavel, v. 3, n. 1, p. 84-89, 2 mar. 2021.
TSAMETIS, Christos P.; ISIDORI, Andrea M. Testosterone replacement therapy: for whom, when and how?. Metabolism, v. 86, p. 69-78, 2018.
WANG, Christina; SWERDLOFF, Ronald S.; IRANMANESH, Ali; DOBS, Adrian; SNYDER, Peter J.; CUNNINGHAM, Glenn; MATSUMOTO, Alvin M.; WEBER, Thomas; GROUP, Nancy Berman The Testosterone Gel Study. Transdermal Testosterone Gel Improves Sexual Function, Mood, Muscle Strength, and Body Composition Parameters in Hypogonadal Men1. The Journal Of Clinical Endocrinology & Metabolism, Washington, v. 85, n. 8, p. 2839-2853, 1 ago. 2000.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Rita de Kássia Costa dos Santos, Ana Beatriz Monteiro de Medeiros, Laíza Andrade Soares Diniz, Victor Veras de Alencar Carvalho, Fábio Farias Balduino, Maria Augusta Silva Cirqueira, Benedito Leandro Francês de Castro, Jardel Pereira Ribeiro, Ricardo Marques de Almeida, Mateus De Lima Santos, Aucelia Cristina Soares de Belchior, Maria Margareth Câmara de Almeida